Myeloma Patients Who Relapse After CAR T-Cell Therapy Have Options

Mount Sinai Researchers Pioneer First Targeted Therapy for Rare T-Cell Lymphoma After CAR T Treatment

Mount Sinai Names Samir Parekh, MD, as Director of the Center of Excellence for Multiple Myeloma

Diabetes May Accelerate Blood Cancer Growth, Yet Survival Outcomes Differ by Race

Potential Treatment Options for Patients With Relapsed Multiple Myeloma Following CAR T-Cell Therapy

Researchers Find Treatment Options for Patients Whose Blood Cancer Relapses After CAR-T

Study shows encouraging therapeutic options for patients with relapsed multiple myeloma

Mount Sinai Researchers Report Encouraging Immunotherapy Option for Relapsed Myeloma Patients

Study Identifies Three-Gene Signature That May Predict Response to Selinexor in Patients With Multiple Myeloma

Blood-Based PD-L1 Tracking Could Offer Improved Response Prediction for Lung Cancer Immunotherapy

Third Dose of COVID-19 Vaccine Significantly Increases Immune Responses in Most Patients With Multiple Myeloma